<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04960059</url>
  </required_header>
  <id_info>
    <org_study_id>CFTSp181</org_study_id>
    <nct_id>NCT04960059</nct_id>
  </id_info>
  <brief_title>NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts</brief_title>
  <official_title>NOTION: iN-home Sampling Of cyTokines in ImmunOtherapy patieNts</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Christie NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Manchester</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Christie NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will explore the ability of patients on first line combination immunotherapy to&#xD;
      sample cytokines at home. The data from this study will be used to evaluate the feasibility&#xD;
      of in-home testing and the ability to analyse patients cytokine profiles retrospectively to&#xD;
      help feed the development of further studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be informed of the study and given a minimum of 24 hours to consider. Once&#xD;
      consented patients will enter the study where they will take cytokine samples at home over a&#xD;
      12 week period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient adherence to protocol defined DBS time points.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of in-home DBS samples passing quality assurance checks in patients receiving CPI therapy by multi-cytokine ELISA.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare cytokine concentrations by DBS sampling and intravenous blood sampling by multi-cytokine ELISA.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Retrospective mapping of immune-related adverse events with cytokine concentrations over time by in-home DBS sampling.</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Patient reported outcomes from semi-structured interviews.</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cancer</condition>
  <condition>Metastatic Melanoma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>This is an observational study</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients receiving checkpoint inhibitor therapy as first line treatment of renal cell&#xD;
        carcinoma, metastatic melanoma or non-small cell lung cancer (in combination with&#xD;
        chemotherapy for NSCLC).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Voluntary informed consent.&#xD;
&#xD;
          -  Aged at least 18 years.&#xD;
&#xD;
          -  Diagnosis of locally advanced or metastatic RCC, Melanoma or NSCLC&#xD;
&#xD;
          -  In the opinion of the investigator deemed suitable to receive first-line combination&#xD;
             immunotherapy (RCC and MM) or combination immunotherapy and chemotherapy (NSCLC).&#xD;
&#xD;
          -  Willingness to comply with scheduled trial procedures.&#xD;
&#xD;
          -  Capable of performing own dry blood sampling procedure, or a carer who is willing and&#xD;
             able to perform them.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous immunotherapy (including any CPI either as single agent on in combination, or&#xD;
             high dose interleukin-2).&#xD;
&#xD;
          -  Judgement by the investigator that the individual should not participate if they are&#xD;
             unlikely to comply with study procedures and requirements.&#xD;
&#xD;
          -  Patients receiving long term oral anticoagulation deemed by the clinician to be at&#xD;
             risk from daily finger pricking.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Leanna Goodwin</last_name>
      <phone>07881842794</phone>
      <email>the-christie.notion@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Donna Graham</last_name>
      <email>donna.graham8@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>immune related adverse event</keyword>
  <keyword>cytokine release</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

